SRV's net sales in Q3 amounted to EUR 159.7m, quite in line with our estimate of EUR 163.
Redeye provides its initial commentary on Nanologica following the Q3 2025 report.
Tagmaster delivers another solid report, beating our expectations across the board (similar to the Q...
Fiskars Q3 adjusted EBIT of EUR 13.9m came 24% (EUR 4.
Redeye is optimistic about the deal with Biossil worth up to USD60m.
* Adj. EBITA 6% vs ABGSC, 1% vs consensus * Norway drove beat; cash flow solid and gearing down to 2...
Redeye considers Polygiene’s Q3 figures to be mixed, with higher-than-expected revenues and gross ma...
Redeye gives its initial take on BONESUPPORT’s Q3 report.
* SEK 800m directed share issue completed, 28% dilution * Next step is a rights issue of ~SEK 750m (...
Sales -7% vs. ABGSCe at SEK 63m * International expansion weighs on earnings * Likely negative conse...
Redeye comments on Dynavox’s Q3 report released earlier this morning, which delivered solid results.
Redeye comments on Litium’s Q3 report, which included a solid organic ARR growth of 11%.
Redeye comments on Evolution’s Q3-results which were weaker than expected, mainly due to lower than ...
Redeye comments on Teneo AI’s Q3 report showing roughly flat q/q ARR growth while the pipeline conti...
Redeye gives its initial take on Xvivo’s Q3 report.
* Adj. EBITA -6% vs ABGSC, -5% vs ModFin consensus * Org.
Atria reported Q3 adjusted EBIT of EUR 25.4m, 7% above LSEG Data & Analytics consensus.
Redeye provides its key takeaways from Cheffelo’s CMD and updates its estimates and valuation follow...
Relais' Q3 adjusted EBITA came in slightly below LSEG Data & Analytics consensus.
We raise adjusted EBITA by 1% for 2026E-27E, following the impressive 80bp y/y margin uplift in Supp...
